Clinical trial
FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles…
NCT00125723 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00125723 |
|---|---|
| Title | FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy |
| Official title | A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Neutropenia |
| Intervention type | Other |
| Interventions | PI Discretion |
| Enrollment | 2,252 |
| Start date | May 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Aug 2, 2005 |
| Last update posted | Dec 23, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: